Perspective Therapeutics’ Cesium-131 featured at ABS conference

Perspective Therapeutics announced that long term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer was presented at the recent American Brachytherapy Society’s, ABS, annual conference held in Vancouver, British Columbia, Canada from June 21-24, 2023. The authors reported that Cesium-131 prostate brachytherapy provided disease-free survival rates of 97.8% and 96%, at 5 and 10 years respectively. “We’re excited that a presentation of long-term clinical data on Cesium-131 brachytherapy for prostate cancer was included at this year’s ABS meeting,” said Thijs Spoor, Perspective’s Chief Executive Officer. He added, “The data shows Cesium-131 brachytherapy offers prostate cancer patients the prospect of disease-free survival of 96% ten years after treatment. This coupled with a favorable side effect profile affirms the value of Cesium-131 brachytherapy as a leading option for prostate cancer treatment.”